Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Abstract Text:

James McGough,James McCracken,James Swanson,Mark Riddle,Scott Kollins,Laurence Greenhill,Howard Abikoff,Mark Davies,Shirley Chuang,Tim Wigal,Sharon Wigal,Kelly Posner,Anne Skrobala,Elizabeth Kastelic,Jaswinder Ghuman,Charles Cunningham,Sharon Shigawa,Robert Moyzis,Benedetto Vitiello,

OBJECTIVE: The Preschool ADHD Treatment Study (PATS) was a NIMH-funded, six-center, randomized, controlled trial to determine the efficacy and safety of immediate-release methylphenidate (MPH-IR), given t.i.d. to children ages 3 to 5.5 years with attention-deficit/hyperactivity disorder (ADHD). METHOD: The 8-phase, 70-week PATS protocol included two double-blind, controlled phases, a crossover-titration trial followed by a placebo-controlled parallel trial. The crossover-titration phase's primary efficacy measure was a combined score from the Swanson, Kotkin, Atkins, M-Flynn, and Pelham (SKAMP) plus the Conners, Loney, and Milich (CLAM) rating scales; the parallel phase's primary outcome measure was excellent response, based on composite scores on the Swanson, Nolan, and Pelham (SNAP) rating scale. RESULTS: Of 303 preschoolers enrolled, 165 were randomized into the titration trial. Compared with placebo, significant decreases in ADHD symptoms were found on MPH at 2.5 mg (p<.01), 5 mg (p<.001), and 7.5 mg (p<.001) t.i.d. doses, but not for 1.25 mg (p<.06). The mean optimal MPH total daily dose for the entire group was 14.2 +/- 8.1 mg/day (0.7+/-0.4 mg/kg/day). For the preschoolers (n=114) later randomized into the parallel phase, only 21% on best-dose MPH and 13% on placebo achieved MTA-defined categorical criterion for remission set for school-age children with ADHD. CONCLUSIONS: MPH-IR, delivered in 2.5-, 5-, and 7.5-mg doses t.i.d., produced significant reductions on ADHD symptom scales in preschoolers compared to placebo, although effect sizes (0.4-0.8) were smaller than those cited for school-age children on the same medication.

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Publishing Authors By Initials

J McGough,J McCracken,J Swanson,M Riddle,S Kollins,L Greenhill,H Abikoff,M Davies,S Chuang,T Wigal,S Wigal,K Posner,A Skrobala,E Kastelic,J Ghuman,C Cunningham,S Shigawa,R Moyzis,B Vitiello,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of the American Academy of Child and Adole

VOLUME: 45

Page Numbers: 1284-93

Journal Abbreviation:

ISSN: 0890-8567

DAY: 3

MONTH: Nov

YEAR: 2006

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8704565

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. Information

Substance Name: Methylphenidate

Registry Number: 113-45-1

Grant and Affiliation Information for Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.

AFFILIATION: Division of Child and Adolescent Psychiatry, New York State Psychiatric Institute/Columbia University, New York, NY 10032, USA. larrylgreenhill@cs.com

Country: United States

AGENCY: United States NIMH

GRANT: U01 MH60943

ACRONYM: MH

MEDLINETA: J Am Acad Child Adolesc Psychi

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD Related Publications

• A bichromatic fluorescent reporter for cell-based screens of alternative splicing.
• A classical likelihood based approach for admixture mapping using EM algorithm.
• Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators.
• Binding of myotrophin/V-1 to actin-capping protein: implications for how capping protein binds to the filament barbed end.
• Body fat and circulating leukocytes in children.
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
• Colorectal cancer screening in the elderly population: disparities by dual Medicare-Medicaid enrollment status.
• Do circulating leucocytes and lymphocyte subtypes increase in response to brief exercise in children with and without asthma?
• Effect of rhIL-6 infusion on GH-->IGF-I axis mediators in humans.
• Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD.
• Evaluation of daily home spirometry for school children with asthma: new insights.
• Identification of prognostic signatures in breast cancer microarray data using Bayesian techniques.
• Issues in maintenance and repairs of wheelchairs: A pilot study.
• LINE-1 Endonuclease-Dependent Retrotranspositional Events Causing Human Genetic Disease: Mutation Detection Bias and Multiple Mechanisms of Target Gene Disruption.
• Lymphoid reconstruction and vaccines.
• Macrophage cell lines produce osteoinductive signals that include bone morphogenetic protein-2.
• Measurement of some novel concepts in psychiatry.
• Patient-specific models for predicting the outcomes of patients with community acquired pneumonia.
• Primitive hematopoietic cell populations reside in the spleen: Studies in the pig, baboon, and human.
• Progress in xenotransplantation following the introduction of gene-knockout technology.
• Quantification of small molecule-receptor affinities and kinetics by acoustic profiling.
• Regional Strength in CAM.
• Regulation of DNA synthesis in bacteria: Analysis of the Bates/Kleckner licensing/initiation-mass model for cell cycle control.
• Shoulder joint kinetics and pathology in manual wheelchair users.
• Stem Cells and CAM.
• The effect of genetic variation in angiotensinogen on serum levels and blood pressure: a comparison of Nigerians and US blacks.
• The impact of FSANZ labelling changes on knowledge of nutrition and allergens by consumer's, health professional's and allergen sufferers.
• The role of titanium surface topography on J774A.1 macrophage inflammatory cytokines and nitric oxide production.
• Titanium surface topography alters cell shape and modulates bone morphogenetic protein 2 expression in the J774A.1 macrophage cell line.
• eCAM: On To Year 4.